Rosalind Advisors Inc. Purchases 1,616,644 Shares of InspireMD, Inc. $NSPR

Rosalind Advisors Inc. lifted its position in InspireMD, Inc. (NYSE:NSPR) by 70.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,905,743 shares of the company’s stock after buying an additional 1,616,644 shares during the period. InspireMD makes up about 3.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 13th largest position. Rosalind Advisors Inc. owned approximately 9.36% of InspireMD worth $9,413,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Raymond James Financial Inc. boosted its stake in InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock valued at $101,000 after acquiring an additional 10,000 shares in the last quarter. Creative Planning acquired a new position in shares of InspireMD during the second quarter worth $44,000. Uniting Wealth Partners LLC acquired a new position in shares of InspireMD during the third quarter worth $51,000. Vestia Personal Wealth Advisors lifted its holdings in shares of InspireMD by 135.7% during the 3rd quarter. Vestia Personal Wealth Advisors now owns 42,425 shares of the company’s stock valued at $102,000 after purchasing an additional 24,425 shares during the last quarter. Finally, Courier Capital LLC boosted its position in shares of InspireMD by 83.3% in the 3rd quarter. Courier Capital LLC now owns 55,000 shares of the company’s stock worth $133,000 after purchasing an additional 25,000 shares in the last quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Stock Performance

NYSE NSPR opened at $1.65 on Friday. The stock has a market cap of $69.91 million, a P/E ratio of -2.20 and a beta of 0.87. InspireMD, Inc. has a 12-month low of $1.51 and a 12-month high of $2.99. The company has a fifty day simple moving average of $1.70 and a two-hundred day simple moving average of $2.01.

Insider Transactions at InspireMD

In related news, insider Shane Thomas Gleason sold 17,593 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $1.62, for a total value of $28,500.66. Following the completion of the transaction, the insider owned 1,174,664 shares in the company, valued at $1,902,955.68. This trade represents a 1.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last ninety days, insiders sold 61,194 shares of company stock valued at $99,188. Company insiders own 29.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on NSPR shares. Loop Capital set a $5.00 target price on InspireMD in a research note on Tuesday, February 24th. Maxim Group assumed coverage on InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 price target for the company. Finally, Lake Street Capital reissued a “buy” rating on shares of InspireMD in a report on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $5.00.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.